MedPath

Pasireotide

Generic Name
Pasireotide
Brand Names
Signifor
Drug Type
Small Molecule
Chemical Formula
C58H66N10O9
CAS Number
396091-73-9
Unique Ingredient Identifier
98H1T17066
Background

Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

Indication

For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.

Associated Conditions
Acromegaly, Cushing's Disease
Clinical Trials
Related News

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial

Phase 2
Completed
Conditions
Neuroendocrine Carcinoma of the Lung and Thymus
Interventions
First Posted Date
2012-03-27
Last Posted Date
2021-04-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
124
Registration Number
NCT01563354
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
First Posted Date
2011-12-08
Last Posted Date
2016-04-07
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT01488487
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

🇺🇸

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Phase 1
Completed
Conditions
Neuroendocrine Tumors
Interventions
Procedure: Sir-sphere Radioembolization
First Posted Date
2011-11-10
Last Posted Date
2018-10-18
Lead Sponsor
Emory University
Target Recruit Count
13
Registration Number
NCT01469572
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1
Completed
Conditions
Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Adenocarcinoma of the Prostate
Interventions
First Posted Date
2011-11-09
Last Posted Date
2021-03-25
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
18
Registration Number
NCT01468532
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

Phase 1
Completed
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2011-06-30
Last Posted Date
2020-09-28
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
20
Registration Number
NCT01385956
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Phase 3
Completed
Conditions
Cushing's Disease
Interventions
Drug: SOM230 LAR 10 mg
Drug: SOM230 LAR 30 mg
First Posted Date
2011-06-16
Last Posted Date
2018-05-22
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT01374906
Locations
🇺🇸

University of California at Los Angeles UCLA Tiverton, Los Angeles, California, United States

🇺🇸

University of Pennsylvania - Clinical Studies Unit Unniv SC, Philadelphia, Pennsylvania, United States

🇺🇸

Emory University School of Medicine/Winship Cancer Institute G2304 - C2301, Atlanta, Georgia, United States

and more 10 locations

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Phase 2
Terminated
Conditions
Islet Cell Tumor
Interventions
First Posted Date
2011-06-16
Last Posted Date
2016-12-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
160
Registration Number
NCT01374451
Locations
🇺🇸

Dana Farber Cancer Institute SC-2, Boston, Massachusetts, United States

🇺🇸

Montefiore Medical Center MMC, Bronx, New York, United States

🇺🇸

Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, United States

and more 2 locations

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Phase 1
Completed
Conditions
Neuroendocrine Tumors
Interventions
First Posted Date
2011-06-02
Last Posted Date
2020-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
29
Registration Number
NCT01364415
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute SC-1, Tampa, Florida, United States

🇺🇸

Dana Farber Cancer Institute SC-6, Boston, Massachusetts, United States

🇺🇸

Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States

and more 1 locations

Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: PLACEBO
First Posted Date
2011-05-20
Last Posted Date
2017-01-25
Lead Sponsor
Alliance Pour La Recherche en Cancerologie
Target Recruit Count
91
Registration Number
NCT01356862
Locations
🇫🇷

Institut Gustave ROUSSY, Villejuif, France

🇫🇷

Tenon Hospital, Paris, France

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Phase 2
Withdrawn
Conditions
Multiple Myeloma in Relapse
Multiple Myeloma
Interventions
First Posted Date
2011-04-05
Last Posted Date
2016-02-12
Lead Sponsor
University of Pittsburgh
Registration Number
NCT01329289
Locations
🇺🇸

Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy